Non-alcoholic fatty liver disease in people with normal body weight
https://doi.org/10.31146/1682-8658-ecg-230-10-36-48
Abstract
The article presents a block of clinical recommendations for the management of patients with non-alcoholic fatty liver disease and normal body weight. This problem is very relevant, since in real clinical practice this condition often remains unrecognized. At the same time, a sufficiently large number of studies have demonstrated that the risks of developing both unfavorable hepatic prognoses and extrahepatic ones, including the development of cardiovascular pathology and cancer, in patients with normal body weight are comparable to patients with overweight and/or obesity. The article proposes an algorithm for the diagnosis and management of patients with NAFLD and normal body weight, including those that are easily feasible in real clinical practice.
About the Authors
S. V. Turkina
Volgograd State Medical University
Russian Federation
Russian Federation
I. A. Tyshchenko
Volgograd State Medical University
Russian Federation
Russian Federation
M. N. Titarenko
Volgograd State Medical University
Russian Federation
Russian Federation
References
1. Ye Q., Zou B., Yeo Y.H. et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020 Aug;5(8):739-752. doi: 10.1016/S2468-1253(20)30077-7.
2. Mark Mascolini. The International Liver Congress™ EASL - European Association for the Study of the Liver. 2021. Available at: https://www.constances.fr/index_EN.php Accessed 05.10.2024.
3. Turkina S.V., Statsenko M.E., Tyshchenko I.A. et al. Assessment of the incidence of non-alcoholic fatty liver disease in patients with normal body weight in the Volgograd region. Therapy. 2023; 9 (S7-69):299. (In Russ.)@@ Туркина С.В., Стаценко М.Е., Тыщенко И.А. и др. Оценка частоты встречаемости неалкогольной жировой болезни печени у пациентов с нормальной массой тела в Волгоградском регионе. Терапия. - 2023. - Т. 9, № S7(69). - С. 299. - EDN: MBHZBA.
4. World Health Organization. Obesity: preventing and managing the global epidemic. 1997, Geneva: WHO.
5. Vilarinho S., Ajmera V., Zheng M. et al. Emerging role of genomic analysis in clinical evaluation of lean individuals with NAFLD. Hepatology. 2021;74(4): 2241-2250. doi: 10.1002/hep.32047.
6. Golabi P., Paik J.M., Arshad T. et al. Mortality of NAFLD according to the body composition and presence of metabolic abnormalities. Hepatol Commun. 2020; 19;4(8): 1136-1148. doi: 10.1002/hep4.1534.
7. Kim H.K., Bae S.J., Lee M.J. et al. Association Of Visceral Fat Obesity, Sarcopenia, And Myosteatosis With Non-Alcoholic Fatty Liver Disease Without Obesity. Clin Mol Hepatol. 2023; 29(4): 987-1001. doi: 10.3350/cmh.2023.0035.
8. Kim D., Chung G.E., Kwak M.S. et al. Body fat distribution and risk of incident and regressed nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14(1): 132-8.e4. doi: 10.1016/j.cgh.2015.07.024.
9. Yang Y.S., Han B.D., Han K. et al. Task force Team of the Obesity Fact Sheet of the Korean Society for the Study of Obesity. Obesity Fact Sheet in Korea, 2021: Trends in Obesity Prevalence and Obesity-Related Comorbidity Incidence Stratified by Age from 2009 to 2019. J Obes Metab Syndr. 2022;31(2): 169-177. doi: 10.7570/jomes22024.
10. Han E., Lee Y.H. Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean? Clin Mol Hepatol. 2023;29(4): 980-983. doi: 10.3350/cmh.2023.0250.
11. Zheng M., Huang D.Q., Konkwo C. et al. Genomic analysis of lean individuals with NAFLD identifies monogenic disorders in a prospective cohort study. JHEP Rep. 2023;5(4):100692. doi: 10.1016/j.jhepr.2023.100692.
12. Xu R., Pan J., Zhou W. et al. Recent advances in lean NAFLD. Biomed Pharmacother. 2022;153:113331. doi: 10.1016/j.biopha.2022.113331
13. Li C., Guo P., Okekunle A.P. et al. Lean non-alcoholic fatty liver disease patients had comparable total caloric, carbohydrate, protein, fat, iron, sleep duration andover time work aso bese non-alcoholic fatty liver disease patients. J Gastroenterol Hepatol. 2019;34(1): 256-262. doi: 10.1111/jgh.14360.
14. Premkumar M., Anand A.C. Lean Fatty Liver Disease: Through Thick and Thin. J Clin Exp Hepatol. 2021;11(5): 523-527. doi: 10.1016/j.jceh.2021.06.011.
15. Sookoian S., Pirola C.J. Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. Aliment Pharmacol Ther. 2017;46(2): 85-95. doi: 10.1111/apt.14112.
16. Young S., Tariq R., Provenza J. et al. Prevalence and Profile of Nonalcoholic Fatty Liver Disease in Lean Adults: Systematic Review and Meta-Analysis. Hepatol Commun. 2020;4(7): 953-972. doi: 10.1002/hep4.1519.
17. Rinella M.E., Neuschwander-Tetri B.A., Siddiqui M.S. et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5): 1797-1835. doi: 10.1097/HEP.0000000000000323.
18. Luo F., Oldoni F., Das A. TM6SF2: A Novel Genetic Player in Nonalcoholic Fatty Liver and Cardiovascular Disease. Hepatol Commun. 2022;6(3): 448-460. doi: 10.1002/hep4.1822.
19. Petta S., Vanni E., Bugianesi E. et al. PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C. Aliment Pharmacol Ther. 2015;41(10): 939-48. doi: 10.1111/apt.13169.
20. Ahmed O.T., Gidener T., Mara K.C. et al. Natural History of Nonalcoholic Fatty Liver Disease With Normal Body Mass Index: A Population-Based Study. Clin Gastroenterol Hepatol. 2022;20(6): 1374-1381.e6. doi: 10.1016/j.cgh.2021.07.016.
21. Ishido S., Tamaki N., Takahashi Y. et al. Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease. BMC Gastroenterol. 2023;23(1): 211. doi: 10.1186/s12876-023-02848-7.
22. Semmler G., Wernly S., Bachmayer S. et al. Non alcoholic Fatty Liver Disease in Lean Subjects: Associations With Metabolic Dysregulation and Cardiovascular Risk-A Single-Center Cross-Sectional Study. Clin Transl Gastroenterol. 2021;12(4): e00326. doi: 10.14309/ctg.0000000000000326.
23. Ye Q., Zou B., Yeo Y.H. et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(8): 739-752. doi: 10.1016/S2468-1253(20)30077-7.
24. Kim Y., Han E., Lee J.S. et al. Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease. Gut Liver. 2022 Mar 15;16(2): 290-299. doi: 10.5009/gnl210084.
25. Turkina S.V., Statsenko M.E., Titarenko M.N. et al. Assessment of cardiovascular risk in patients with non-alcoholic fatty liver disease and normal body weight. Therapy 2023;9 S7(69):298 (In Russ.)@@ Туркина С.В., Стаценко М.Е., Титаренко М.Н. и др. Оценка сердечно-сосудистого риска у пациентов с неалкогольной жировой болезнью печени и нормальной массой тела. Терапия 2023. Т. 9. № S7(69). С. 298
26. Gao Y., Zhao T., Song S. et al. Lean non alcoholic fatty liver disease and risk of incident type 2 diabetes mellitus: A literature review and meta-analysis. Diabetes Res Clin Pract. 2023 Jun;200:110699. doi: 10.1016/j.diabres.2023.110699.
27. Li N., Xang W., Wu S. et al. Association between the lean nonalcoholic fatty liver disease and risk of incident type 2 diabetes in a healthy population of Northwest China: a retrospective cohort study with a 2-year follow-up period. Front Endocrinol (Lausanne). 2023 Jun26;14:1173757. doi: 10.3389/fendo.2023.1173757.
28. Тurkina S.V., Statsenko M.E., Tyshchenko I.A. et al. Cardiometabolic disorders in a patient with non-alcoholic fatty liver disease and normal body weight. Bulletin of the Volgograd State Medical University. 2024;21(3):109-117. (In Russ) doi: 10.19163/1994-9480-2024-21-3-109-117.@@ Туркина С.В., Стаценко М.Е., Тыщенко И.А. и др. Кардиометаболические нарушения у пациента с неалкогольной жировой болезнью печени и нормальной массой тела. Вестник Волгоградского государственного медицинского университета. 2024; 21(3): 109-117. doi:10.19163/1994-9480-2024-21-3-109-117.
29. Turkina S.V., Statsenko M.E., Tyshchenko I.A. et al. Diagnostic significance of evaluation of triglyceride-glucose index in patients with non-alcoholic fatty liver disease and normal body weight. Volgograd Journal of Medical Research. 2024; 21(3): 34-39. (In Russ)@@ Туркина С.В., Стаценко М.Е., Тыщенко И.А. и др. Диагностическая значимость оценки триглицерид-глюкозного индекса у пациентов с неалкогольной жировой болезнь печени и нормальной массой тела. Волгоградский научно-медицинский журнал. 2024;21(3): 34-39.
30. Fracanzani A.L., Petta S., Lombardi R. et al. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. Clin Gastroenterol Hepatol. 2017 Oct;15(10):1604-1611.e1. doi: 10.1016/j.cgh.2017.04.045.
31. Hagström H., Nasr P., Ekstedt M. et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. Hepatol Commun. 2017 Nov 30;2(1): 48-57. doi: 10.1002/hep4.1124.
32. Leung J.C., Loong T.C., Wei J.L. et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology. 2017 Jan;65(1):54-64. doi: 10.1002/hep.28697.
33. Nabi O., Lapidus N., Boursier J. et al. Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-COStudy). Hepatology. 2023 Jul 1;78(1):272-283. doi: 10.1097/HEP.0000000000000329.
34. Chon Y.E., Kim H.J., Choi Y.B. et al. Decrease in waist-to-hip ratio reduced the development of chronic kidney disease in non-obese non-alcoholic fatty liver disease. SciRep. 2020; (10): 8996. doi.org/10.1038/s41598-020-65940-y.
35. Chan K.E., Ong EY.H, Chung C.H. et al. Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies. Clin Gastroenterol Hepatol. 2024 Mar;22(3):488-498.e14. doi: 10.1016/j.cgh.2023.09.018.
36. Liu Z., Lin C., Suo C. et al. Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers. Metabolism. 2022 Feb;127:154955. doi: 10.1016/j.metabol.2021.154955.
37. Souza M., Diaz I., Barchetta I. et al. Gastro intestinalc ancersinleanindividuals with non-alcoholic fatty liver disease: A systematic review and meta-analysis. Liver Int. 2024 Jan;44(1): 6-14. doi: 10.1111/liv.15763.
38. Chen N., Zhou J., Wang K. et al. Non-obese or lean non-alcoholic fatty liver disease was associated with increased risk of cancer in patients with type 2 diabetes mellitus. BMJ Open Diabetes Res Care. 2023 Feb;11(1): e003066. doi: 10.1136/bmjdrc-2022-003066.
39. Wongtrakul W., Charatcharoenwitthaya N., Charatcharoenwitthaya P. Lean non-alcoholic fatty liver disease and the risk of all-cause mortality: An updated meta-analysis. Ann Hepatol. 2024 May-Jun;29(3): 101288. doi: 10.1016/j.aohep.2024.10128.
40. Wijarnpreecha K., Li F., Lundin S.K. et al. Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities. Aliment Pharmacol Ther. 2023 May;57(9):1014-1027. doi: 10.1111/apt.17424.
41. [Non-alcoholic fatty liver disease] Clinical guidelines Ministry of Health of the Russian Federation 2022. ID: 748.@@ Клинические рекомендации «Неалкогольная жировая болезнь печени», 2022. ID: 748.
42. Order of Rospotrebnadzor dated 07.07.2020 N 379 «On approval of training (educational) programs on healthy nutrition». Available at: https://legalacts.ru/doc/prikaz-rospotrebnadzora-ot-07072020-n-379-ob-utverzhdenii-obuchaiushchikh/(Accessed: 05.10.2024.)@@ Приказ Роспотребнадзора от 07.07.2020 N 379 «Об утверждении обучающих (просветительских) программ по вопросам здорового питания» https://legalacts.ru/doc/prikaz-rospotrebnadzora-ot-07072020-n-379-ob-utverzhdenii-obuchaiushchikh/
43. Svarovskaya A.V., Garganeeva A.A. Anthropometric indices obesity and cardiometabolic risk: is there a link? Cardiovascular Therapy and Prevention. 2021;20(4): 2746. (In Russ.) doi: 10.15829/1728-8800-2021-2746.@@ Сваровская А.В., Гарганеева А.А. Антропометрические индексы ожирения и кардиометаболический риск: есть ли связь? Кардиоваскулярная терапия и профилактика. 2021;20(4):2746. doi:10.15829/1728-8800-2021-2746.
44. Andreasson A., Carlsson A.C., Önnerhag K. et al. Waist/Hip Ratio Better Predicts Development of Severe Liver Disease Within 20 Years Than Body Mass Index: A Population - based Cohort Study. Clin Gastroenterol Hepatol. 2017 Aug;15(8): 1294-1301.e2. doi: 10.1016/j.cgh.2017.02.040.
45. Chan D.C., Watts G.F., Barrett P.H.R. et al. Waist circum ference, waist-to-hipratio and body mass index aspredictors of adipose tissuecom partments in men. QJM: An International Journal of Medicine. 2003;96(6): 441-447. doi: 10.1093/qjmed/hcg069.
46. Ahmad N., Adam S.I., Nawi A.M. et al. Abdominal obesity indicators: waist circum ference or waist-to-hip ratio in Malaysian adults population.Int J Prev Med. 2016;7: 82. doi: 10.4103/2008-7802.183654.
47. Roriz C., Karla A., Passos S. et al. Anthropometric clinical indicators in the assessment of visceral obesity: an update. Nutr Clín Diet Hosp. 2016;36(2):168-79. doi: 10.12873/362carneirororiz.
48. Gadekar T., Dudeja P., Basu I. et al. Correlation of visceral body fat with waist-hip ratio, waist circumference and body mass index in healthy adults: A cross sectionalstudy. Med J Armed Forces India. 2020 Jan;76(1): 41-46. doi: 10.1016/j.mjafi.2017.12.001.
49. Tran N.T.T., Blizzard C.L., Luong K.N. et al. The importance of waist circumference and body mass index in cross-sectional relationships with risk of cardiovascular disease in Vietnam. PLoS One. 2018;13(5): e0198202. doi: 10.1371/journal.pone.0198202.
50. Moreira V.C., de Souza Silva C.M. et al. Altered Visceral Adipose Tissue Predictors and Women’s Health: A Unicenter Study.Int J Environ Res Public Health. 2022 May 1;19(9):5505. doi: 10.3390/ijerph19095505
51. Samouda H., Dutour A., Chaumoitre K., et al. VAT=TAAT-SAAT: innovative anthropometric model to predict visceral adipose tissue without resort to CT - Scanor DXA. Obesity (Silver Spring). 2013;21(1): E41-50. doi: 10.1002/oby.20033.
52. Lee S., Kim K.W., Lee J. Sex-specific Cut off Values of Visceral Fat Area for Leanvs. Overweight /Obese Non alcoholic Fatty Liver Disease in Asians. J Clin Transl Hepatol. 2022 Aug 28;10(4): 595-599. doi: 10.14218/JCTH.2021.00379.
53. Weinberg E.M., Trinh H.N., Firpi R.J. et al. Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Comorbid Diseases. Clin Gastroenterol Hepatol. 2021 May;19(5):996-1008.e6. doi: 10.1016/j.cgh.2020.06.066.
54. Fracanzani A.L., Petta S., Lombardi R. et al. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. Clin Gastroenterol Hepatol. 2017 Oct;15(10):1604-1611.e1. doi: 10.1016/j.cgh.2017.04.045.
55. Hagström H., Nasr P., Ekstedt M. et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. Hepatol Commun. 2017 Nov 30;2(1):48-57. doi: 10.1002/hep4.1124.
56. Younes R., Govaere O., Petta S. et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? Gut. 2022 Feb;71(2):382-390. doi: 10.1136/gutjnl-2020-322564.
57. Long M.T., Noureddin M., Lim J.K. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. Gastroenterology. 2022 Sep;163(3):764-774.e1. doi: 10.1053/j.gastro.2022.06.023.
58. Fu C., Wai J.W., Nik Mustapha N.R. et al. Performance of Simple Fibrosis Scoresin Nonobese Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2020 Nov;18(12):2843-2845.e2. doi: 10.1016/j.cgh.2019.09.027.
59. Loomba R., Adams L.A. Advances in non-invasive assessment of hepatic fibrosis. Gut. 2020 Jul;69(7):1343-1352. doi: 10.1136/gutjnl-2018-317593.
60. Mansour D., Grapes A., Herscovitz M. et al. Embedding assessmen to fliver fibrosis in to routine diabetic review inprimary care. JHEP Rep. 2021 Apr 22;3(4):100293. doi: 10.1016/j.jhepr.2021.100293.
61. Mózes F.E., Lee J.A., Selvaraj E.A. et al. LITMUS Investigators. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut. 2022 May;71(5):1006-1019. doi: 10.1136/gutjnl-2021-324243.
62. Lazebnik L.B., Golovanova E.V., Turkina S.V. et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Experimental and Clinical Gastroenterology. 2021;1(1): 4-52. (In Russ) doi: 10.31146/1682-8658-ecg-185-1-4-52.@@ Лазебник Л.Б., Голованова Е.В., Туркина С.В. и др. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021 Mar 17;185(1): 4-52 doi.org/10.31146/1682-8658-ecg-185-1-4-52
63. Liebe R., Esposito I., Bock H.H. et al. Diagnosis and management of secondary causes of steatohepatitis. J Hepatol. 2021 Jun;74(6):1455-1471. doi: 10.1016/j.jhep.2021.01.045.
64. Welty F.K. Hypobetalipoproteinemia and abetalipoproteinemia: liver disease and cardiovascular disease. Curr Opin Lipidol. 2020 Apr;31(2): 49-55. doi: 10.1097/MOL.0000000000000663.
65. A-Kader H.H. Lysosomal acid lipase deficiency: a form of non-obese fatty liver disease (NOFLD). Expert Rev Gastroenterol Hepatol. 2017 Oct;11(10): 911-924. doi: 10.1080/17474124.2017.1343144.
66. Tidwell J., Wu G.Y. Unique Genetic Features of Lean NAFLD: A Review of Mechanisms and Clinical Implications. J Clin TranslHepatol. 2024 Jan 28;12(1): 70-78. doi: 10.14218/JCTH.2023.00252.
67. Liebe R., Esposito I., Bock H.H. et al. Diagnosis and management of secondary causes of steatohepatitis. J Hepatol. 2021 Jun;74(6):1455-1471. doi: 10.1016/j.jhep.2021.01.045.
68. Vilar-Gomez E., Martinez-Perez Y., Calzadilla-Bertot L. et al. Weight Loss Through Life style Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015 Aug;149(2):367-78.e5; quiz e14-5. doi: 10.1053/j.gastro.2015.04.005.
69. Haigh L., Kirk C., El Gendy K. et al. The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis. Clin Nutr. 2022 Sep;41(9):1913-1931. doi: 10.1016/j.clnu.2022.06.037.
70. Fernández T., Viñuela M., Vidal C. et al. Lifestyle changes in patients with non-alcoholic fattyl iver disease: A systematic review and meta-analysis. PLoS One. 2022 Feb 17;17(2): e0263931. doi: 10.1371/journal.pone.0263931.
71. Keating S.E., Sabag A., Hallsworth K. et al. Exercise in the Management of Metabolic-Associated Fatty Liver Disease (MAFLD) in Adults: A Position Statement from Exercise and Sport Science Australia. Sports Med. 2023 Dec;53(12):2347-2371. doi: 10.1007/s40279-023-01918-w.
72. Jin Y.J., Kim K.M., Hwang S. et al. Exercise and diet modification in non-obese non-alcoholic fatty liver disease: analysis of biopsies of living liver donors. J Gastroenterol Hepatol. 2012 Aug;27(8):1341-7. doi: 10.1111/j.1440-1746.2012.07165.x.
73. Hamurcu Varol P., Kaya E., Alphan E. et al. Role of intensive dietary and lifestyle interventions in the treatment of lean nonalcoholic fatty liver disease patients. Eur J Gastroenterol Hepatol. 2020 Oct;32(10):1352-1357. doi: 10.1097/MEG.0000000000001656.
74. Sinn D.H., Kang D., Cho S.J. et al. Weight change and resolution of fatty liver in normal weight individuals with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1): e529-e534. doi: 10.1097/MEG.0000000000002158.
75. Wong V.W., Chan R.S., Wong G.L. et al.Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol. 2013 Sep;59(3):536-42. doi: 10.1016/j.jhep.2013.04.013.
76. Wong V.W., Wong G.L., Chan R.S. et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol. 2018 Dec;69(6):1349-1356. doi: 10.1016/j.jhep.2018.08.011.
77. Kim N.H., Kim J.H., Kim Y.J. et al. Clinical and metabolic factors associated with development and regression of nonalcoholic fatty liver disease in nonobese subjects. Liver Int. 2014 Apr;34(4): 604-11. doi: 10.1111/liv.12454.
78. Mark Mascolini. The International Liver Congress™ EASL - European Association for the Study of the Liver. 2021. Available at: https://www.constances.fr/index_EN.php Accessed 05.10.2024.
79. Semmler G., Datz C., Trauner M. Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease. Clin Mol Hepatol. 2023 Feb;29(Suppl): S244-S260. doi: 10.3350/cmh.2022.0364.
80. Taheri S., Lin L., Austin D. et al. Shorts leep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. PLoS Med. 2004 Dec;1(3): e62. doi: 10.1371/journal.pmed.0010062.
81. Cizza G., Piaggi P., Rother K.I. et al. Sleep Extension Study Group. Hawthorne effect with transient behavioral and biochemical changes in a randomized controlled sleep extension trial of chronically short-sleeping obese adults: implications for the design and interpretation of clinical studies. PLoS One. 2014 Aug 20;9(8): e104176. doi: 10.1371/journal.pone.0104176.
82. Romero-Gómez M., Zelber-Sagi S., Trenell M. Treatment of NAFLD withdiet, physical activity and exercise. J Hepatol. 2017 Oct;67(4): 829-846. doi: 10.1016/j.jhep.2017.05.016.
83. Hashida R., Kawaguchi T., Bekki M. et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. J Hepatol. 2017 Jan;66(1): 142-152. doi: 10.1016/j.jhep.2016.08.023.
84. Diagnostics and correction of lipid metabolism disorders in order to prevent and treat of atherosclerosis Russian recommendations VII revision. The Journal of Atherosclerosis and Dyslipidemias (JAD). 2020;1(38): 7-42 (in Russ.) doi: 10.34687/2219-8202.JAD.2020.01.0002.@@ Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и дислипидемии. 2020;1(38):7-42. doi: 10.34687/2219-8202.JAD.2020.01.0002.
85. Sergiyenko I.V.Russian сlinical guidelines on lipid metabolism disorders 2024. What’s new? RMJ. 2023;4: 12-16. (In Russ)@@ Сергиенко И.В. Российские клинические рекомендации по нарушению липидного обмена 2024 г. Что нового? РМЖ. 2023;4:12-16.
86. Drapkina O.M., Mokrysheva N.G., Shestakova M.V. et al. Clinical observation of patients with prediabetes by a general practitioner in primary health care / Drapkina O.M., Mokrysheva N.G., Shestakova M.V. et al. Moscow: Federal State Budgetary Institution “NMIC TPM” of the Ministry of Health of Russia, 2024, 38 p. ISBN: 978-5-6052598-2-4.@@ Драпкина О.М., Мокрышева Н.Г., Шестакова М.В. и др. Диспансерное наблюдение пациентов с предиабетом врачом-терапевтом в первичном звене здравоохранения / Драпкина О.М., Мокрышева Н.Г., Шестакова М.В. и др. - М.: ФГБУ «НМИЦ ТПМ» Минздрава России, 2024 г., 38 с. ISBN: 978-5-6052598-2-4.
87. [Type 2 diabetes mellitus in adults]. Clinical guidelines Ministry of Health of the Russian Federation 2022. ID 290.@@ Сахарный диабет 2 типа у взрослых. Клинические рекомендации Министерства здравоохранения РФ. 2022. ID 290.
88. [Chronic kidney disease (CKD)]. Clinical guidelines Ministry of Health of the Russian Federation 2024. ID: 469.@@ Хроническая болезнь почек (ХБП). Клинические рекомендации Министерства здравоохранения РФ 2024. ID: 469.
89. Danpanichkul P., Suparan K., Kim D. et al. What Is New in Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals: From Bench to Bedside. J ClinMed. 2024 Jan 3;13(1):278. doi: 10.3390/jcm13010278.
90. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Obes Facts. 2024;17(4): 374-444. doi: 10.1159/000539371.
Review
For citations:
Turkina S.V., Tyshchenko I.A., Titarenko M.N. Non-alcoholic fatty liver disease in people with normal body weight. Experimental and Clinical Gastroenterology. 2024;(10):36-48. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-230-10-36-48
Views:
7
Email this article 